|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Ciba-Geigy
gptkb:Searle_Pharmaceuticals
|
|
gptkbp:activities
|
Dopamine D2 receptor antagonist
Serotonin 5-H T2 A receptor antagonist
|
|
gptkbp:approves
|
gptkb:2010
gptkb:U._S._Food_and_Drug_Administration
|
|
gptkbp:brand
|
gptkb:Latuda
|
|
gptkbp:category
|
gptkb:unknown
Category B
|
|
gptkbp:class
|
atypical antipsychotic
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
hypersensitivity to lurasidone
concomitant use of strong CY P3 A4 inducers
concomitant use of strong CY P3 A4 inhibitors
|
|
gptkbp:developed_by
|
gptkb:Sunovion_Pharmaceuticals
|
|
gptkbp:dosage_form
|
gptkb:tablet
40 to 160 mg per day
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lurasidone
|
|
gptkbp:ingredients
|
C22 H24 N2 O2 S
|
|
gptkbp:interacts_with
|
antidepressants
anticonvulsants
other antipsychotics
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
2026
|
|
gptkbp:is_used_for
|
treatment of schizophrenia
treatment of bipolar depression
|
|
gptkbp:lifespan
|
18 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:population
|
gptkb:Person
adults
adolescents
|
|
gptkbp:research_focus
|
gptkb:historical_event
schizophrenia
bipolar disorder
|
|
gptkbp:side_effect
|
anxiety
nausea
insomnia
akathisia
somnolence
|
|
gptkbp:social_structure
|
thienobenzodiazepine
|
|
gptkbp:type_of
|
367514-24-5
|